Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B J Druker

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 5, 2002
ST1571: a paradigm for clinical trials of molecularly targeted agentsB J Druker
Cancer Journal (Sudbury, Mass.)|August 16, 2001
Current treatment approaches for chronic myelogenous leukemiaB J Druker
Lancet (London, England)|January 11, 2002
Chronic myeloid leukemia. Sceptical scientistsB J Druker
Journal of Hematotherapy & Stem Cell Research|January 19, 2002
Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. GlaserB J Druker
Biochimica Et Biophysica Acta|January 13, 1998
Protein tyrosine kinases and cancerK S Kolibaba, B J Druker
The Journal of Clinical Investigation|January 5, 2000
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemiaB J Druker, N B Lydon
Journal of Internal Medicine|July 17, 2001
Chronic myelogenous leukaemia--new therapeutic principlesM E O'Dwyer, B J Druker
Cancer Investigation|January 1, 1983
BCG-induced macrophages as suppressor cellsB J Druker, H T Wepsic
Current Opinion in Oncology|November 21, 2000
Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemiaM E O'Dwyer, B J Druker
The Oncologist|June 26, 2001
STI571: targeting BCR-ABL as therapy for CMLM J Mauro, B J Druker
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 5, 2002
ST1571: a paradigm for clinical trials of molecularly targeted agentsB J Druker
Cancer Journal (Sudbury, Mass.)|August 16, 2001
Current treatment approaches for chronic myelogenous leukemiaB J Druker
Lancet (London, England)|January 11, 2002
Chronic myeloid leukemia. Sceptical scientistsB J Druker
Journal of Hematotherapy & Stem Cell Research|January 19, 2002
Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. GlaserB J Druker
Biochimica Et Biophysica Acta|January 13, 1998
Protein tyrosine kinases and cancerK S Kolibaba, B J Druker
The Journal of Clinical Investigation|January 5, 2000
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemiaB J Druker, N B Lydon
Journal of Internal Medicine|July 17, 2001
Chronic myelogenous leukaemia--new therapeutic principlesM E O'Dwyer, B J Druker
Cancer Investigation|January 1, 1983
BCG-induced macrophages as suppressor cellsB J Druker, H T Wepsic
Current Opinion in Oncology|November 21, 2000
Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemiaM E O'Dwyer, B J Druker
The Oncologist|June 26, 2001
STI571: targeting BCR-ABL as therapy for CMLM J Mauro, B J Druker
Pageof 13